These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 9668534

  • 1. Hydroxyurea therapy in thalassemia.
    Loukopoulos D, Voskaridou E, Stamoulakatou A, Papassotiriou Y, Kalotychou V, Loutradi A, Cozma G, Tsiarta H, Pavlides N.
    Ann N Y Acad Sci; 1998 Jun 30; 850():120-8. PubMed ID: 9668534
    [Abstract] [Full Text] [Related]

  • 2. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW.
    N Engl J Med; 1993 Jan 14; 328(2):73-80. PubMed ID: 7677965
    [Abstract] [Full Text] [Related]

  • 3. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
    Pearson HA.
    Adv Pediatr; 1996 Jan 14; 43():309-34. PubMed ID: 8794181
    [No Abstract] [Full Text] [Related]

  • 4. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.
    Blood Cells Mol Dis; 2000 Oct 14; 26(5):453-66. PubMed ID: 11112383
    [Abstract] [Full Text] [Related]

  • 5. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.
    Acta Haematol; 1995 Oct 14; 94(3):128-34. PubMed ID: 7502628
    [Abstract] [Full Text] [Related]

  • 6. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP, Hillery CA, Brown ER, Misiewicz V, Labotka RJ.
    J Pediatr; 1996 Jun 14; 128(6):820-8. PubMed ID: 8648542
    [Abstract] [Full Text] [Related]

  • 7. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
    Di Maggio R, Hsieh MM, Zhao X, Calvaruso G, Rigano P, Renda D, Tisdale JF, Maggio A.
    Int J Mol Sci; 2018 Feb 28; 19(3):. PubMed ID: 29495591
    [Abstract] [Full Text] [Related]

  • 8. Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment.
    Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.
    Ann N Y Acad Sci; 2005 Feb 28; 1054():250-6. PubMed ID: 16339672
    [Abstract] [Full Text] [Related]

  • 9. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S, Barton FB, Moore RD, Terrin ML, Steinberg MH, Dover GJ, Ballas SK, McMahon RP, Castro O, Orringer EP.
    Medicine (Baltimore); 1996 Nov 28; 75(6):300-26. PubMed ID: 8982148
    [Abstract] [Full Text] [Related]

  • 10. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
    Goldberg MA, Brugnara C, Dover GJ, Schapira L, Charache S, Bunn HF.
    N Engl J Med; 1990 Aug 09; 323(6):366-72. PubMed ID: 1695325
    [Abstract] [Full Text] [Related]

  • 11. Hemoglobin switching protocols in thalassemia. Experience with sodium phenylbutyrate and hydroxyurea.
    Dover GJ.
    Ann N Y Acad Sci; 1998 Jun 30; 850():80-6. PubMed ID: 9668530
    [Abstract] [Full Text] [Related]

  • 12. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A, Segal-Kupershmit D, Zalman L, Levin C, Abu Hana M, Palmor H, Luder A, Attias D.
    Pediatr Hematol Oncol; 1999 Jun 30; 16(3):221-32. PubMed ID: 10326220
    [Abstract] [Full Text] [Related]

  • 13. Use of hydroxyurea and recombinant erythropoietin in management of homozygous beta0 thalassemia.
    Kohli-Kumar M, Marandi H, Keller MA, Guertin K, Hvizdala E.
    J Pediatr Hematol Oncol; 2002 Dec 30; 24(9):777-8. PubMed ID: 12468925
    [Abstract] [Full Text] [Related]

  • 14. Increased erythropoietin level induced by hydroxyurea treatment of sickle cell patients.
    Papassotiriou I, Voskaridou E, Stamoulakatou A, Loukopoulos D.
    Hematol J; 2000 Dec 30; 1(5):295-300. PubMed ID: 11920206
    [Abstract] [Full Text] [Related]

  • 15. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
    Borg J, Phylactides M, Bartsakoulia M, Tafrali C, Lederer C, Felice AE, Papachatzopoulou A, Kourakli A, Stavrou EF, Christou S, Hou J, Karkabouna S, Lappa-Manakou C, Ozgur Z, van Ijcken W, von Lindern M, Grosveld FG, Georgitsi M, Kleanthous M, Philipsen S, Patrinos GP.
    Pharmacogenomics; 2012 Oct 30; 13(13):1487-500. PubMed ID: 23057549
    [Abstract] [Full Text] [Related]

  • 16. Clinical experience with fetal hemoglobin induction therapy in patients with β-thalassemia.
    Musallam KM, Taher AT, Cappellini MD, Sankaran VG.
    Blood; 2013 Mar 21; 121(12):2199-212; quiz 2372. PubMed ID: 23315167
    [Abstract] [Full Text] [Related]

  • 17. Response to hydroxyurea among Kuwaiti patients with sickle cell disease and elevated baseline HbF levels.
    Adekile A, Menzel S, Gupta R, Al-Sharida S, Farag A, Haider M, Akbulut N, Mustafa N, Thein SL.
    Am J Hematol; 2015 Jul 21; 90(7):E138-9. PubMed ID: 25851995
    [No Abstract] [Full Text] [Related]

  • 18. Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential.
    Perrine SP.
    Pediatr Ann; 2008 May 21; 37(5):339-46. PubMed ID: 18543545
    [Abstract] [Full Text] [Related]

  • 19. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K, Jain D, Gattani S, Jijina F, Nadkarni A, Sawant P, Nair S, Mohanty D, Ghosh K, Colah R.
    Blood Cells Mol Dis; 2009 May 21; 42(1):25-31. PubMed ID: 18954999
    [Abstract] [Full Text] [Related]

  • 20. Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cells.
    Moutouh-de Parseval LA, Verhelle D, Glezer E, Jensen-Pergakes K, Ferguson GD, Corral LG, Morris CL, Muller G, Brady H, Chan K.
    J Clin Invest; 2008 Jan 21; 118(1):248-58. PubMed ID: 18064299
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.